Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:03:08 EST Mon 16 Feb 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:MIRM - MIRUM PHARMACEUTICALS INC - https://mirumpharma.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MIRM - Q0.275.00·105.300.1103.10    105.74  36.8801Feb 13Feb 1015 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-10 22:45U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-05 08:51U:MIRMNews ReleaseMirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI(TM) Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
2026-02-05 08:00U:MIRMNews ReleaseMirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI(TM) for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
2026-01-26 08:00U:MIRMNews ReleaseMirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
2026-01-12 17:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-12 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
2026-01-07 16:01U:MIRMNews ReleaseMirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-19 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
2025-12-10 19:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-12-08 08:00U:MIRMNews ReleaseMirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
2025-12-01 08:10U:MIRMNews ReleaseMirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
2025-11-25 16:02U:MIRMNews ReleaseMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-11-10 20:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-07 08:10U:MIRMNews ReleaseMirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI(TM) and Volixibat Clinical Programs at AASLD's The Liver Meeting(TM)
2025-11-04 16:01U:MIRMNews ReleaseMirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-03 16:05U:MIRMNews ReleaseMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-10-28 16:02U:MIRMNews ReleaseMirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
2025-10-10 19:45U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-10 18:45U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-08 08:00U:MIRMNews ReleaseMirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study